Press Release

Kirkland Represents GlaxoSmithKline on Sale of Stake in Innoviva Inc

Kirkland & Ellis advised GlaxoSmithKline plc (LSE/NYSE: GSK) on its agreement with Innoviva, Inc. (NASDAQ: INVA), a royalty management company, to sell all of its approximately 32 million shares of common stock of Innoviva back to Innoviva at a price of $12.25 per share, raising gross proceeds of approximately $392 million. Following settlement of the transaction, GSK will no longer hold any Innoviva stock.

Read the GSK press release

The Kirkland team was led by corporate partners Dvir Oren and Daniel Wolf.